billHR6455Event Thursday, December 4, 2025Analyzed

Health Insurance Premium Fairness Act of 2025

Neutral

Summary

HR6455 is an early-stage bill referred to the House Ways and Means Committee with no defined funding mechanism, no market-moving provisions, and no identifiable near-term impact on publicly traded companies. No market action is warranted.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR6455 is in early legislative stage with no committee action since referral on December 4, 2025
  • 2.Bill modifies tax credit calculation for Medicare premiums but does not appropriate any funding
  • 3.No identifiable near-term market impact on any publicly traded company
  • 4.Three cosponsors, all Democrats, indicate limited bipartisan support
  • 5.No market action warranted at this stage

Market Implications

Currently, no actionable market implications exist from this legislation. If the bill were to advance out of committee and gain momentum, managed care companies with Medicare Advantage exposure (UNH, HUM, CNC) could see modest beneficiary enrollment shifts, but only with significant legislative advancement. For retail investors, no position adjustments are necessary based on HR6455.

Full Analysis

  1. On December 4, 2025, Representative Levin (D-CA) introduced the Health Insurance Premium Fairness Act of 2025 (HR6455), a bill that would amend the Internal Revenue Code to allow certain Medicare premiums paid by household members to reduce an applicable taxpayer's health insurance premium tax credit under section 36B. The bill has been referred to the House Committee on Ways and Means and has three cosponsors. With only one committee referral and no hearings or markups, this bill is in the earliest legislative stage. 2) The bill does not authorize or appropriate any funding. It modifies a tax credit calculation, which could reduce federal revenue, but the Congressional Budget Office has not yet released a score. The effective date applies to coverage months after December 31, 2025, but since no further action has occurred since introduction, the provision is not yet in effect. 3) At this procedural stage, no publicly traded companies are directly affected. The bill's provisions target Medicare premium payments by household members—a relatively narrow tax credit adjustment. Managed care organizations (e.g., $UNH, $HUM, $CNC) that offer Medicare Advantage plans could see a marginal impact if the bill eventually passed, as lower out-of-pocket premium costs might shift some beneficiary enrollment, but the bill has not moved beyond referral. Managed care organizations with exposure to Medicare Advantage include UnitedHealth Group, Humana, and Cigna. However, with the bill stalled at first-step referral, there is no basis for market action. 4) No real market data was provided for this event, but the legislative velocity is effectively zero—three actions all on the same day (introduction and referral). For context, most bills never advance past this stage; fewer than 5% of introduced bills become law. 5) The legislative path remaining includes committee consideration, potential markup, House floor vote, Senate introduction and passage, and presidential action. Without broader congressional support—indicated by only three cosponsors, all Democrats—the bill faces very long odds. No market action is warranted until or unless the bill advances significantly.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

proclamationJul 13, 2026

Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security

President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).

Exec OrderJun 25, 2026

Advancing Regenerative Agriculture and Strengthening American Farm Resilience

This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.

Exec OrderJun 3, 2026

Implementing Schedule Policy/Career in the Excepted Service

This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →